GSK stock: Jefferies reissues Buy rating for GSK stock at GBp 2,500

Published on 10/21/2026 at 15:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK reports results on October 28, 2026. GSK stock costs EUR 22.40 on October 21, 2026, 0.81 percent above the Xetra close.

Analyst target and reporting date

Jefferies reissued a Buy rating and a GBp 2,500 target for GSK on October 20, 2026.
GSK is scheduled to report third-quarter results on October 28, 2026.
GSK stock costs EUR 22.40 at Lang & Schwarz on October 21, 2026 at 3:36 p.m. CEST, 0.81 percent above the Xetra close of October 20, 2026.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

Jefferies reissued a Buy rating for GSK and kept a GBp 2,500 price target in a report issued on October 20, 2026, according to MarketBeat. The target places attention on GSK's pipeline and upcoming third-quarter figures. At Lang & Schwarz, GSK was trading at EUR 22.40 on October 21, 2026 at 3:36 p.m. CEST, 0.81 percent above the Xetra close of October 20, 2026 at EUR 22.22.

Second-quarter growth sets the base

GSK's second-quarter 2026 turnover reached GBP 8.41 billion, up 5 percent at constant exchange rates, while core operating profit increased 7 percent to GBP 2.80 billion. Core operating margin was 33.3 percent for the quarter, according to the period review published by Drillr.

The mix remains important. Specialty medicines and vaccines support growth, while general medicines declined 9 percent at constant exchange rates in the second quarter. Core research and development spending rose 13 percent, faster than turnover, making the third-quarter margin a central number for investors.

Price position and valuation

The October 20 Xetra close of EUR 22.22 provides the comparison for the current German quotation. In London, MarketBeat reported a 12-month range of GBp 1,592 to GBp 2,282, a price to earnings ratio of 15.86 and a market capitalization of GBP 74.87 billion in its October 20, 2026 market update. These figures use the London listing and are separate from the euro quotation.

What comes next for GSK?

GSK is scheduled to publish third-quarter 2026 results before the market opens on October 28, 2026, with an earnings call scheduled for 8:00 a.m. ET, according to MarketBeat. The same report cites consensus estimates of USD 1.33 adjusted earnings per share and USD 11.74 billion in revenue. The figures will test whether specialty growth can offset higher research spending and pressure on general medicines.

A September 22, 2026 filing with the SEC identifies GB00BN7SWP63 as GSK plc ordinary shares admitted to trading on the London Stock Exchange. For the stock, the upcoming results and the Jefferies target offer two distinct reference points: operating delivery in the third quarter and external valuation at GBp 2,500.

GSK stock stays near EUR 22

The euro quotation was EUR 22.40 at Lang & Schwarz on October 21, 2026 at 3:36 p.m. CEST, 0.81 percent above the Xetra close of October 20, 2026 at EUR 22.22. The next scheduled company event is the third-quarter report on October 28, 2026.

The further course of trading is shown by the continuously updated real-time quote of GSK stock.